Back to results
US 2026/0098071 A1Published application
GLP-1 Analog and Use Thereof in Treatment of GLP-1 Related Diseases
OwnerTao Suninventor
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a novel human glucagon-like peptide-1 (GLP-1) analog. Compared with the natural sequence of GLP-1, the GLP-1 analog has a remarkable effect in improving GLP-1-related diseases such as obesity, type 2 diabetes mellitus (T2DM), and fatty liver (FL), as well as mood disorders such as anxiety and depression.
Claims20
A glucagon-like peptide-1 (GLP-1) analog, comprising amino acid sequences of Formula I:
- Formula I
- (SEQ ID NO:
- 2)
- HX2X3 GTF TSD VSS YLE GQA AKX21 FIA WLX27 KX29RX31
- wherein,
- X2 is selected from the group consisting of valine, isoleucine, glycine, threonine, leucine and serine;
- X3 is selected from the group consisting of serine and alanine;
- X21 is selected from the group consisting of arginine and lysine;
- X27 is selected from the group consisting of serine and alanine;
- X29 is selected from the group consisting of alanine, serine, threonine and methionine;
- and
- X31 is selected from the group consisting of alanine, serine, threonine and methionine.
9 more elements
A GLP-1 analog, comprising a polypeptide sequence of Formula II:
- Formula II
- (SEQ ID NO:
- 1)
- HGE GTF TSD VSS YLE GQA AKE FIA WLV KSRA
1 more element
Dependencies are inferred from the claim text.